mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.082 |
0.01 |
mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.071 |
0.01 |
mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.082 |
0.02 |
mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.085 |
0.02 |
mRNA |
BRD-K16147474 |
CTRPv2 |
pan-cancer |
AAC |
0.092 |
0.02 |
mRNA |
NSC 74859 |
CTRPv2 |
pan-cancer |
AAC |
0.09 |
0.02 |
mRNA |
BRD-K51490254 |
CTRPv2 |
pan-cancer |
AAC |
0.087 |
0.02 |
mRNA |
dexamethasone |
CTRPv2 |
pan-cancer |
AAC |
0.077 |
0.02 |
mRNA |
selumetinib:MK-2206 (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.082 |
0.02 |
mRNA |
Doxorubicin |
gCSI |
pan-cancer |
AAC |
-0.13 |
0.02 |